Calyxt receives EU patent for use of CRISPR/Cas9 for genome editing

Calyx (CLXT) announced the issuance of European patent number 3008186, which claims methods to create gene-edited plants by the transient delivery of sequence-specific nucleases, including CRISPR/Cas9. This patent, granted by the European Patent Office, is owned by Cellectis and licensed exclusively to Calyxt (CLLS).

https://thefly.com/landingPageNews.php?id=2838260